Nabil Noureddin (@NoureddinNabil) profile picture

Advanced endoscopy fellow @WCM_GI via @UCSD_GI & @unlvmedicine

Joined November 2019
Photo by Nabil Noureddin (@NoureddinNabil)Photo by Nabil Noureddin (@NoureddinNabil)Photo by Nabil Noureddin (@NoureddinNabil)Photo by Nabil Noureddin (@NoureddinNabil)Photo by Nabil Noureddin (@NoureddinNabil)Photo by Nabil Noureddin (@NoureddinNabil)Photo by Nabil Noureddin (@NoureddinNabil)Photo by Nabil Noureddin (@NoureddinNabil)Photo by Nabil Noureddin (@NoureddinNabil)Photo by Nabil Noureddin (@NoureddinNabil)
Happy for the graduating IM residents and can’t wait to see their future accomplishments. I am grateful to @ucsdim for the Top Fellow award. It was an honor to work with an outstanding group of residents! #GITwitter
17
5
80
5,359
Nabil Noureddin retweeted
Join us on Friday, April 10, 2026 for 'ALD-ALLY 2026' - a virtual and in-person conference with 7.25 ACCME Credits - Alcohol-associated Liver Disease patients deserve ALcohol LiteracY eventleaf.com/e/ALDALLY2026 #MedEd
2
1
5
766
Had the opportunity to present Grand Rounds on the evolving role of advanced endoscopy in GI oncology — from ESD to interventional EUS and how these techniques are reshaping management and patient care. Grateful to the incredible advanced endoscopy mentors @WCM_GI, @drbobbybrown , and my amazing program director @ReemSharaiha for the mentorship, guidance, and support. Thanks as well to our general GI fellows and staff who make this work possible.
4
2
1
13
3,034
Walking through the colon for #ColorectalCancerAwarenessMonth. Colorectal cancer remains the 2nd leading cause of cancer death in the U.S., yet it is highly preventable with screening. Colonoscopy and polyp detection save lives. @ReemSharaiha @WCM_GI #DavidCarrLocke @nyphospital @bsc_endoscopy
2
2
1
17
3,541
Several members of our team, including fellows, attended the #NYSGE Annual Dinner this week. They celebrated NYSGE's achievements and educational initiatives led by president @ReemSharaiha! @FeliceSchnoll @katzpo @Michelle_Lee_MD @DrCriccoLizza @AdamBuckholz @WCMDeptofMed
3
10
763
A big congratulations to Dr. Tamas Gonda, newly appointed as President of the @NYSGE‼️Thank you also to @ReemSharaiha on her service & leadership as President over the past year. We look forward to great things ahead in NY #gastroenterology & #endoscopy‼️ @MarkPochapin
1
1
1
14
980
Prof. Mazen Noureddin presents: “Selecting therapy in MASH: matching drugs to phenotypes.” Highlighting a practical, phenotype-driven framework tailoring treatment to metabolic profile, fibrosis risk, and comorbidities. #BestofTLM #SASLT #AASLD #MASH
4
16
1,158
Nabil Noureddin retweeted
Artículo de Revisión Ensayos clínicos en MASH y la cartera de medicamentos: un inminente tsunami Noureddin #LiverX shorturl.at/oir5U
7
30
2,095
Nabil Noureddin retweeted
Drs Patrick T. Magahis and SriHari Mahadev discuss “Outcomes of endoscopic ultrasound–guided liver biopsy using 22-gauge versus 19-gauge needles with a novel hydrostatic sampling technique." youtu.be/cFEn4tbjCuI #GITwitter @PatrickMagahis @ReemSharaiha @MarkHanscomMD
4
13
1,120
A powerful Presidential Address by NYSGE President @ReemSharaiha at the @nysge Annual Meeting — past lessons, present innovation, and the future of endoscopy. @WCM_GI
2
4
14
964
Highly anticipated NYSGE Annual Course—an exceptional program led by NYSGE President and Director of Endoscopy @ReemSharaiha, with an outstanding faculty. @WCM_GI @NYSGE
Please join us for the NYSGE Annual Course! Pertinent didactics, hands-on endoscopy training and incredible live cases! @NYSGE @ReemSharaiha @NikhilKumtaMD @laurenkhanna @shandrawes @EndoscopyOA @MouenKhashab @DrBloodandGuts
2
9
869
Prof. David Carr-Locke invites you to the 33rd @CedarsSinai International Endoscopy Symposium and Future of Endoscopy Meeting Jan 28–31, 2026. A legacy meeting shaping the future of endoscopy. Open to all cedars.cloud-cme.com/endosco…
1
2
1
20
1,013
Safety and efficacy of weekly pemvidutide versus placebo for metabolic dysfunction-associated steatohepatitis (IMPACT): 24-week results from a multicentre, randomised, double-blind, phase 2b study - @TheLancet #livertwitter – at Hunters Creek Village, TX
Safety and efficacy of weekly pemvidutide versus placebo for metabolic dysfunction-associated steatohepatitis (IMPACT): 24-week results from a multicentre, randomised, double-blind, phase 2b study - The Lancet thelancet.com/journals/lance…
1
6
26
3,212
Nabil Noureddin retweeted
50 yrs of endoscopy wisdom - Carr-Locke ▪️Do best for patients ▪️Make every scope your best ▪️Keep growing ▪️Keep publishing ▪️Support fellows ▪️Value nurses & techs ▪️Happy home = job ▪️Happy job = home ▪️Partnerships matter ▪️Don’t take too serious 🎥 vumedi.com/video/50-years-of…
3
20
95
6,450
The 2️⃣0️⃣2️⃣5️⃣ advanced endoscopy 🥼fellows coming 💫 together to🍎 learn from this ✨stellar faculty about 🩻 ERCP and 💎cholangioscopy. Thank you @bostonsci ‼️@ASGEendoscopy #Gastroenterology #womeningi
1
3
13
1,777
Local Post-Procedural Cryoprevention Significantly Reduces the Incidence of Post-ERCP Pancreatitis Azuma, et al.   📕 doi.org/10.14309/ajg.0000000…   @MLongMD @JasmohanBajaj
7
107
17
261
42,592
Nabil Noureddin retweeted
You are really leading this field, @NoureddinMD. Truly awesome
New in the @TheLancet :Arguably the highest fibrosis improvement in #MASH trials to date #livertwitter @ebtapper @schattenbergJ @AlkhouriNaim @akerotx @scottisaacsmd @NoureddinNabil @ArunJSanyalVCU Safety and efficacy of once-weekly efruxifermin versus placebo in metabolic dysfunction-associated steatohepatitis (HARMONY): 96-week results from a multicentre, randomised, double-blind, placebo-controlled, phase 2b trial - The Lancet thelancet.com/journals/lance…
1
4
25
4,980
Huge step forward for MASH patients — and for the hepatology field!
New in the @TheLancet :Arguably the highest fibrosis improvement in #MASH trials to date #livertwitter @ebtapper @schattenbergJ @AlkhouriNaim @akerotx @scottisaacsmd @NoureddinNabil @ArunJSanyalVCU Safety and efficacy of once-weekly efruxifermin versus placebo in metabolic dysfunction-associated steatohepatitis (HARMONY): 96-week results from a multicentre, randomised, double-blind, placebo-controlled, phase 2b trial - The Lancet thelancet.com/journals/lance…
9
541
A breakthrough study for our MASH patients! @NoureddinMD
SYMMETRY trial: Efruxifermin was previously shown to reduce fibrosis in patients with stage 2 or 3 fibrosis caused by metabolic dysfunction–associated steatohepatitis. Research findings in patients with compensated cirrhosis are summarized in a new Quick Take video. nej.md/44vzhCN
11
708
Nabil Noureddin retweeted
SYMMETRY trial: Efruxifermin was previously shown to reduce fibrosis in patients with stage 2 or 3 fibrosis caused by metabolic dysfunction–associated steatohepatitis. Research findings in patients with compensated cirrhosis are summarized in a new Quick Take video. nej.md/44vzhCN
1
21
1
64
16,189